451 related articles for article (PubMed ID: 23623807)
1. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T-cell engaging antibodies for cancer therapy.
Baeuerle PA; Reinhardt C
Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.
Nagorsen D; Baeuerle PA
Exp Cell Res; 2011 May; 317(9):1255-60. PubMed ID: 21419116
[TBL] [Abstract][Full Text] [Related]
4. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
6. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
[TBL] [Abstract][Full Text] [Related]
7. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
8. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
10. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
11. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
Ross SL; Sherman M; McElroy PL; Lofgren JA; Moody G; Baeuerle PA; Coxon A; Arvedson T
PLoS One; 2017; 12(8):e0183390. PubMed ID: 28837681
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
13. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
14. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
15. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
16. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA; Kufer P; Bargou R
Curr Opin Mol Ther; 2009 Feb; 11(1):22-30. PubMed ID: 19169956
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
18. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
Yuraszeck T; Kasichayanula S; Benjamin JE
Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
[TBL] [Abstract][Full Text] [Related]
19. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies engage T cells for antitumor immunotherapy.
Choi BD; Cai M; Bigner DD; Mehta AI; Kuan CT; Sampson JH
Expert Opin Biol Ther; 2011 Jul; 11(7):843-53. PubMed ID: 21449821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
